H.C. Wainwright downgraded Summit Therapeutics (NASDAQ:SMMT) to Neutral from Buy.
The downgrade follows competitive pressure from Merck's sacituzumab tirumotecan data.
The price target was removed.
Summit Therapeutics downgraded to neutral
H.C. Wainwright downgrades Summit Therapeutics to Neutral due to competitive pressure from Merck.
More News
Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.
Stifel reiterates IBM Buy after $1bn Chips Act award
Stifel reiterates IBM Buy rating after $1bn Chips Act award for quantum computing. Stock up 15%.
Stifel Maintains Buy on Deckers Outdoor at $140
Stifel reiterates Buy rating on Deckers Outdoor with $140 target. Stock shows strong growth potential and attractive valuation.
Argus Upgrades CAVA Group Stock Rating
Argus upgraded CAVA Group to Buy with a $92 target, citing improved restaurant traffic. Stock returned 66% in six months.
BofA raises Zoom price target on strong margins
BofA Securities raised Zoom's price target to $105, citing strong margins and free cash flow after Q1 results beat expectations.
Workday price target cut by Needham
Needham cuts Workday price target to $180 from $300, maintaining Buy rating. Workday beats revenue and income estimates, raises operating guidance.
BioMarin Neutral Rating, $50 Target by HC Wainwright
H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.
RBC Capital Initiates Essent Group at Sector Perform
RBC Capital starts Essent Group with Sector Perform, $68 target. Limited earnings growth expected through 2028, with ROE below 12%.
Dell Stock Rises on AI Momentum
Evercore ISI reaffirms Dell Outperform on AI momentum. Dell stock up 102% YTD, AI factory serves 5,000+ customers. New products unveiled.
Wolfe Research Starts Alto Neuroscience with Outperform
Wolfe Research initiates coverage on Alto Neuroscience with an outperform rating and $35 price target. ALTO-207 pipeline highlighted.
Oppenheimer Raises EnerSys Target to $250
Oppenheimer raises EnerSys price target to $250, citing strong fiscal Q4 results and upbeat guidance. Learn about key growth drivers.
RBC Capital Raises Advance Auto Parts Price Target
RBC Capital raises Advance Auto Parts price target to $65 after strong Q1 results with 3.5% sales growth and EPS beat.
...